Harmony Biosciences Shares Rise After Q2 Earnings, Product Revenue Increase

MT Newswires Live08-04

Harmony Biosciences (HRMY) shares were up 6.2% in early Tuesday trading after the company posted higher Q2 results.

The company reported Q2 earnings of $1.28 per diluted share, up from $0.68 a year earlier.

Analysts polled by FactSet expected $0.96.

Net product revenue for the quarter ended June 30 was $261.3 million, up from $200.5 million a year earlier.

Analysts expected revenue of $250.8 million.

Harmony reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

As of June 30, the company said it had $962.5 million in cash, cash equivalents and investments.

Price: 37.81, Change: +2.21, Percent Change: +6.19

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment